CHASE Registry of Patients With Pulmonary Hypertension Receiving Targeted Therapy

Recruiting now

Conditions studied: Pulmonary Hypertension

In brief

CHina Registry for the chAracteristics and Management strategieS of patiEnts With Pulmonary Hypertension Using Targeted Therapy (CHASE Study)

Key facts

Study ID

NCT06135909

Run by

Chinese Pulmonary Vascular Disease Research Group

People needed

5000

Starts

2020-01-01

Expected to finish

2027-12-31

Last updated by the study team

2024-01-18

Who can join

Age: 18 and older, up to 85. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Sign informed consent;
• Between the ages of 18 and 85;
• Clinical diagnosis of pulmonary hypertension, using or planning to use pulmonary hypertension targeted drugs (including any one or more of the following: prostacyclin analogues, endothelin receptor antagonists, phosphodiesterase inhibitors, soluble guanylate cyclase agonists and prostacyclin receptor agonists).

You may not qualify if…

• Have a history of mental illness or drug or poison addiction, and can not sign informed consent or can not cooperate with the experimental study;
• Patients with malignant tumor and other diseases and life expectancy of less than half a year;
• Short-term (less than 2 weeks) patients taking targeted drugs for pulmonary hypertension

Where it is running

• Center for Respiratory and Pulmonary Vascular Diseases, Fuwai hospital, CAMS & PUMC — Beijing, China (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.